The IGFBP-7/IGF-1 ratio showed a significant graded increase from controls (0.43) to asymptomatic left ventricular diastolic dysfunction (0.48) to heart failure with preserved ejection fraction (0.68).
Cross-Sectional (n=300)
No
Does the IGFBP-7/IGF-1 ratio correlate with diastolic function and serve as a biomarker for HFpEF in patients referred for cardiac assessment?
The IGFBP-7/IGF-1 ratio correlates with the severity of diastolic dysfunction and may serve as a novel biomarker for identifying patients with HFpEF.
Absolute Event Rate: 0.68% vs 0.43%
p-value: p=<0.001
BACKGROUND: Insulin-like growth factor binding protein-7 (IGFBP-7) modulates the biological activities of insulin-like growth factor-1 (IGF-1). Previous studies demonstrated the prognostic value of IGFBP-7 and IGF-1 among patients with systolic heart failure (HF). This study aimed to evaluate the IGF1/IGFBP-7 axis in HF patients with preserved ejection fraction (HFpEF). METHODS: Serum IGF-1 and IGFBP-7 levels were measured in 300 eligible consecutive patients who underwent comprehensive cardiac assessment. Patients were categorized into 3 groups including controls with normal diastolic function (n = 55), asymptomatic left ventricular diastolic dysfunction (LVDD, n = 168) and HFpEF (n = 77). RESULTS: IGFBP-7 serum levels showed a significant graded increase from controls to LVDD to HFpEF (median 50.30 43.1-55.3 vs. 54.40 48.15-63.40 vs. 61.9 51.6-69.7, respectively, P < 0.001), whereas IGF-1 levels showed a graded decline from controls to LVDD to HFpEF (120.0 100.8-144.0 vs. 112.3 88.8-137.1 vs. 99.5 72.2-124.4, p < 0.001). The IGFBP-7/IGF-1 ratio increased from controls to LVDD to HFpEF (0.43 0.33-0.56 vs. 0.48 0.38-0.66 vs. 0.68 0.55-0.88, p < 0.001). Patents with IGFB-7/IGF1 ratios above the median demonstrated significantly higher left atrial volume index, E/E' ratio, and NT-proBNP levels (all P ≤ 0.02). CONCLUSION: In conclusion, this hypothesis-generating pilot study suggests the IGFBP-7/IGF-1 axis correlates with diastolic function and may serve as a novel biomarker in patients with HFpEF. A rise in IGFBP-7 or the IGFBP-7/IGF-1 ratio may reflect worsening diastolic function, adverse cardiac remodeling, and metabolic derangement.
Barroso et al. (Fri,) conducted a cross-sectional in Heart failure with preserved ejection fraction (HFpEF) (n=300). IGFBP-7/IGF-1 ratio vs. Controls (normal diastolic function) was evaluated on IGFBP-7/IGF-1 ratio across patient groups (p=<0.001). The IGFBP-7/IGF-1 ratio showed a significant graded increase from controls (0.43) to asymptomatic left ventricular diastolic dysfunction (0.48) to heart failure with preserved ejection fraction (0.68).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: